A multisite phase 1 clinical trial for NT-I7 is underway in patients with relapsed/refractory large B-cell lymphoma.
A long-acting human IL-7, NT-I7, fused with hybrid Fc (rhIL-7-hyFc) was shown to enhance the proliferation, persistence, and cytotoxicity of human CAR T cells in xenogeneic mouse models and murine CAR T cells in syngeneic mouse models, leading to long-term tumor-free survival, according to results from a preclinical study recently published in Nature Communications.1 These results indicate that NT-17, which is being developed by NeoImmuneTech, could prove useful in improving suboptimal CAR T-cell activity.
In murine models of both acute myeloid leukemia and B-cell lymphoma, NT-17 significantly prolonged survival by enhancing the efficacy of CAR-T therapy. Additionally, NT-17 allowed for a 5-fold reduction in the number of CAR T-cells needed at the time of infusion to prolong survival.2
“Enhancement of CAR T cell activity has the potential to improve patient outcomes by reducing target positive relapse in patients with CD19+ B cell malignancies,” the investigators wrote.1
The study utilized sophisticated mouse models of B-cell lymphoma and acute myeloid leukemia and an immune competent syngeneic mouse model of acute promyelocytic leukemia.2 NT-17 was shown to protect CD19-targeting CAR –T-cells from cell death, which promoted their proliferation in the presence of CD19+ tumor cells. While CAR T-cells that expanded in the presence of NT-I7 were less differentiated, it was noted that they possessed equivalent effector cytokine secreting abilities.2
“Importantly, we did not see any evidence of toxicity with the combination of mCART19 and rhIL-7-hyFc in the immunocompetent mice,” the investigators noted.1 “Additionally, murine CAR T-cell numbers in immunocompetent mice did not reach the astronomical levels seen with human CAR T-cells in NSG mice after rhIL-7-hyFc. The NSG model provides proof of principle that this reagent is effective on human CAR T-cells in vivo, but the lack of endogenous lymphocytes in these mice is likely responsible for the massive expansion of CAR T-cells, and in human subjects, the kinetics of CAR T-cell expansion is expected to be more akin what was seen in the immunocompetent mice.”
Se Hwan Yang, PhD, president and chief executive officer of NeoImmuneTech, Inc., said in a statement, “Those results demonstrate the broad applicability of NT-I7 for cellular therapy, in addition to its well-documented benefits as a long-acting human IL-7 that has the potential to amplify T cells across the subsets, boost the immune system, and enhance the anti-tumor response in people with hematologic malignancies and solid tumors.”2
A multisite phase 1b clinical trial (NCT05075603) is currently underway to pursue the results of this study further, and will investigate NT-I7 with CD19-targeting CAR T-cells for the treatment of relapsed/refractory large B-cell lymphomas. NT-I7 will be administered via intramuscular injection following tisagenlecleucel (tisa-cel; Kymriah, Novartis) infusion. Primary outcome measures include safety and tolerability with end points such as incidence, nature, and severity of adverse events and the maximum tolerated dose. Secondary outcome measures include preliminary anti-tumor activity of NT-I7 with end points such as overall response rate, duration of response, progression-free survival, and overall survival.
FDA Announces Probe Into bluebird's Elivaldogene Autotemcel for Hematologic Malignancies
November 27th 2024Approved as Skysona, the therapy has been reported to be related to cases of hematologic malignancies, including life-threatening instances of myelodysplastic syndrome and acute myeloid leukemia.